FDA Pharmacoepidemiology Deputy Director To Be ODE V's Bull
This article was originally published in The Pink Sheet Daily
Executive Summary
When the Office of Drug Evaluation V is eliminated as part of the anticipated reorganization of the Office of New Drugs, Jonca Bull is expected to move to the open post, which will report to Paul Seligman.
You may also be interested in...
FDA Pharmacoepidemiology Office Adds Jonca Bull
ODE V director joins effective May 2 as deputy director, leaving only one major vacancy in OPaSS. Reorganization of the Office of New Drugs is eliminating ODE V.
FDA Pharmacoepidemiology Office Adds Jonca Bull
ODE V director joins effective May 2 as deputy director, leaving only one major vacancy in OPaSS. Reorganization of the Office of New Drugs is eliminating ODE V.
FDA Reorganization Of New Drug Office Would Split Neuropharmaceutical Division
Neurology and psychiatry drugs would be reviewed in separate divisions under the proposed restructuring. The reorganization, which aims to group products by therapeutic indications and integrate the review of biologics and drugs, would eliminate ODE V.